Bombesin-like peptides (BLPs) are mitogens for bronchial epithelial cells and small cell lung carcinomas, and increase fetal lung growth and maturation in utero and in organ cultures. BLPs are hydrolyzed by the enzyme CD10/neutral endopeptidase 24.11 (CD10/NEP) which is expressed in bronchial epithelium and functions to inhibit BLP-mediated growth of small cell lung carcinomas. To determine whether CDI0/NEP regulates peptide-mediated lung development, we administered a specific CD1O/NEP inhibitor, SCH32615, to fetal mice in utero from gestational days e15-17. Fetal lung tissues were evaluated on el8 for: (a) growth using [3HIthymidine incorporation into nuclear DNA; and (b) maturation using: 13H1-choline incorporation into surfactant phospholipids, electron microscopy for type II pneumocytes, and Northern blot analyses for surfactant apoproteins A, B, and C. Inhibition of CD10 / NEP stimulated [3HIthymidine incorporation into DNA (70% above baseline, P < 0.005), 13Hlcholine incorporation into surfactant phospholipids (38% above baseline, P < 0.005), increased numbers of type II pneumocytes (36% above baseline, P = 0.07), and fivefold higher surfactant protein A transcripts (P < 0.05). CD10/NEP-mediated effects were completely blocked by the specific bombesin receptor antagonist, IDPhe'2, Leu14jbombesin. These observations suggest that CD10/NEP regulates fetal lung growth and maturation mediated by endogenous BLPs. (J. Clin. Invest. 1993. 91:1969-1973.) Key words: metalloendopeptidase * autocrine growth factors * fetal lung development * cell surface enzyme * common acute lymphoblastic leukemia antigen
Introduction
The cell membrane antigen CD 10 / common acute lymphoblastic leukemia antigen was shown by molecular cloning to be identical to the enzyme neutral endopeptidase 24.1 1 (NEP)' (1) (2) (3) (4) . This zinc metalloprotease cleaves a variety of bioactive peptides including tachykinins such as bradykinin and substance P (2, (4) (5) (6) . CD1O/NEP downregulates neurogenic inflammation ofthe lung by modulating locally effective concentrations of tachykinins (7) (8) (9) (10) . The enzyme has been found to hydrolyze bombesin-like peptides (BLPs) within the conserved seven amino acid terminus required for biological activity (reviewed in 11, 12, 13 ) . Recently, hydrolysis of BLPs by CD10/ NEP was demonstrated to modulate autocrine growth of small cell carcinomas ofthe lung (SCLCs): inhibition ofCD10/NEP stimulated the growth of BLP-responsive SCLCs and addition of CD10/NEP inhibited the growth of SCLC in a dose-dependent fashion ( 12) .
In addition to stimulating the autocrine growth of certain SCLCs, BLPs increase the clonal growth of adult human bronchial epithelial cells and the proliferation of pulmonary fibroblasts (14) (15) (16) . In recent studies, these peptides were also shown to stimulate the proliferation and maturation of normal fetal lung. Gastrin-releasing peptide (GRP; mammalian bombesin) transcripts and immunoreactivity were detectable in pulmonary neuroendocrine cells of human fetal lung as early as 8 wk gestation, with peak transcript levels occurring at midgestation ( 17) . In murine fetal lung, maximal GRP expression occurred on embryonic days 17 and 18 (e 17-18) . Exogenous bombesin administered to pregnant mice during this time period stimulated the proliferation and maturation of fetal lung as assessed by functional, biochemical, and ultrastructural analyses. In related studies, BLPs stimulated the proliferation and maturation of human fetal lung organ cultures ( 18 ) .
Those studies demonstrated that CD10/NEP was expressed by immature bronchial epithelial cells in first trimester human fetal lung and that inhibition of the enzyme was associated with increased proliferation of human fetal lung organ cultures. To further explore the role of CD10/NEP in fetal lung development in utero, we administered a long-acting inhibitor ofCDO/NEP (SCH326 15 ) to pregnant mice and subsequently evaluated parameters ofboth fetal lung proliferation and maturation. Herein, we report that the inhibition of CD10/NEP results in a significant enhancement of fetal lung growth and maturation that is completely blocked by a specific bombesin receptor antagonist.
Methods
Reverse-transcribed PCR (RT-PCR) analysesfor CDJO/NEP and actin transcripts. Lungs were harvested from untreated fetal mice on the morning of gestational days 12-18 (e12-18) and total RNA was prepared using the quanidine isothiocyanate (GTC)-CsCI method ( 19) . RNA (obtained from three to eight litters for each time point) was reverse transcribed and cDNA was amplified by PCR as previously described using actin primers (20) and CD1O/NEP primers corre- (21) . Southern blots ofthe PCR products were probed with an end-labeled internal oligonucleotide specific for either CD1O/NEP (1319-1338 bp) or actin (20) . For semi-quantitative RT-PCR, conditions were determined such that the number of cycles was approximately one-third maximal and thus within the linear range of detection. Furthermore, increased RNA input led to a linear increase in RT-PCR signal for both actin and CDlO/NEP (comparing three doses over a two log scale). Therefore, there was a linear correlation between the relative amounts ofgiven mRNAs present in the products ofthe same reverse transcription reaction, which could then be compared to actin as a control reference housekeeping mRNA.
In vivo administration ofSCH32615 to pregnant mice. We chose to administer SCH32615 (Schering-Plough Corp., Bloomfield, NJ) from e 15-17 because BLP effects were most apparent at e 17-18 in previous studies (22) ,MCi/ml) for 4 h at 37°C in 5% C02/air on a rocking platform. Tissues were harvested and analyzed for 3H-labeled DNA, DNA content, 3H-labeled SPC, and protein content as outlined below.
For determination of 3H-SPC, lipids were extracted from cell homogenates with chloroform/ methanol and [ 3H ]choline incorporation into phosphatidylcholine was determined as previously described (22) .
Protein was determined by the method of Bradford with BSA as standard (25) .
[3H]thymidine incorporation into acid-precipitable counts was carried out as previously described (26) . DNA was assayed after trichloroacetic acid precipitation by the method ofBurton (27 Ultrastructural analyses. Pregnant mice were treated from gestational days 15-17 with either PBS or SCH32615 (0.1 and 1.0 mg/kg). Lungs were harvested on e18, fixed in 2.5% glutaraldehyde/ 1% paraformaldehyde, and routinely processed for electron microscopic analyses. Blocks were selected within a group such that both proximal and distal portions ofthe lung were equally represented for each ofthe four groups. The number of nucleated epithelial cells containing lamellar bodies (LBs) was quantitated by an observer without knowledge ofthe Northern (RNA) blot hybridization. Total RNA was prepared from freshly harvested fetal lung tissues using the guanidinium isothiocyanate-cesium chloride method (28) . 10 Mg/lane of total RNA was fractionated on formaldehyde denaturing agarose gels and transferred to nitrocellulose by standard capillary transfer ( 19) . After baking, blots were prehybridized for 12 h. The blots were probed with cDNAs encoding murine CDIO/NEP (29) , surfactant apoproteins (SPA) A, B, and C (kindly donated by Dr. Joanna Floros, Pennsylvania State University, Hershey, PA [30] ) and a housekeeping G-protein (G-alpha-2, donated by Dr. Randall Reed, Johns Hopkins University School ofMedicine, Baltimore, MD [ 31 ] ). cDNA probes were synthesized from gelpurified cDNA inserts corresponding to coding sequences from mouse CDIO/NEP (2,400 bp), rat SP-A (750 bp), SP-B (500 bp), and SP-C (800 bp), and G-protein ( 1,800 bp) using the random-primed oligonucleotide method (32) . Blots were hybridized with 106 cpm/ml at 420C for 24 20 mM, pH 7.4). After washing at 420C in 2X SSC, 0.1% SDS, blots were exposed overnight to Kodak XAR film with an intensifying screen and subsequently developed. Densitometry was carried out by three-dimensional integration of the area of whole bands on autoradiograms using a densitometer (model 300A; Molecular Dynamics, Inc., Sunnyvale, CA).
Statistical analyses. Data were statistically analyzed using the unpaired Student's t test.
Results CDJO/NEP transcript levels in fetal mouse lung. CD10/NEP transcript levels were detectable at low levels as early as e 12 by semi-quantitative reverse PCR analyses (Fig. 1) . Peak CD10/ NEP transcript levels occurred at e 15-18 by reverse PCR analyses ( Fig. 1) and by Northern blotting (data not shown).
In vivo studies. There was no significant difference between saline controls and SCH326 15-treated fetal mice with regards to intrauterine viability, total fetal weight, or developmental defects. No histological differences were observed between saline controls and SCH32615-treated animals by light microscopic examination on e17-18. In both sets ofanimals, all cells lining the primitive alveoli were simple cuboidal as expected for the canalicular and saccular stages of murine lung development during this time period.
We chose to administer SCH32615 from el 5-17 because BLP effects were most apparent at e 17-e 18 in previous studies (22) and peak CD10/NEP transcript levels occurred at e 17-18 ( Fig. 1 ) . The administration of SCH32615 from el 5-17 in e12 e13 e14 e15 e16 e17 e18 A B Am., Figure 1 . CD10/NEP transcript levels in fetal mouse lung. Lungs were harvested from untreated fetal mice on the morning of e 12-18 and total RNA was prepared using the GTC-CsCl method ( 19) . RNA (obtained from three to eight litters for each time point) was reverse transcribed and cDNA was amplified by PCR as previously described using actin primers (20) and CDI0/NEP primers corresponding to 1,208-1,228 and 1,667-1,648 bp of mouse CDO0 sequence (21 ) . Southern blots of the PCR products were probed with an end-labeled internal oligonucleotide specific for the gene product of interest: (A) CD1O/NEP (1,319-1,338 bp); (B) actin (20) . Conditions were defined such that the RT-PCR analyses were semiquantitative, with increased RNA input leading to a linear increase in signal for both actin and CD10/NEP. utero led to increased fetal lung growth as assessed by incorporation of [3H]thymidine into nuclear DNA. In Fig. 2A , the pooled data from nine experiments are shown. Both the 0.1 and 1.0 mg/kg doses of SCH32615 led to significantly elevated thymidine incorporation in murine fetal lungs harvested on e18 (0.1 mg/kg: 17% increase, P < 0.05; and 1.0 mg/kg: 69% increase, P < 0.005, respectively, Fig. 2A) .
To determine whether CD10/NEP inhibition also affected fetal lung maturation, we measured the incorporation of [3H]-choline into SPC, a key rate-determining step in the biochemical pathway of surfactant phospholipid synthesis. Pooled data from nine experiments are shown in Fig. 2B . In animals treated with SCH32615, significantly elevated choline incorporation was observed on e 18 (38% increase, 1.0 mg/kg dose, P < 0.005). Fetal serum corticosterone levels did not differ between PBS controls and SCH32615-treated mice (data not shown).
To determine whether the in vivo effect of SCH32615 was mediated by BLPs, mice were concurrently treated with 100 ,4g/kg of a specific bombesin receptor antagonist, [D-Phe 2, Leu"4]bombesin (24) (BR in Fig. 2 To determine whether the inhibition of CD0/NEP might affect the earlier embryonic and pseudoglandular stages oflung development (el2-e16), SCH32615 (1 mg/kg) was administered to pregnant mice from e 12-14. Fetal lung tissues were harvested from treated and control animals on e 14, 15, 16, and 17. Pooled results from three experiments are shown in Fig. 3 . The administration of SCH32615 from e 12-14 did not affect thymidine incorporation in e 14 murine fetal lungs. However, e 12-14 CD10/NEP inhibition increased thymidine incorporation in el5-17 fetal lungs (el5, 18% increase, P < 0.05; e16, 37% increase, P < 0.005; and el7, 107% increase, P < 0.05, respectively). Early SCH32615 administration resulted in increased thymidine and choline incorporation on e 18 that was similar to that observed using the e 15-el 7 injection schedule ( Fig. 2 and data not shown) .
Electron microscopy. LBs are one of the morphological manifestations of surfactant and are thus a sensitive indicator of early type II pneumonocyte differentiation, which is a critical step in lung maturation. For this reason, we performed ultrastructural analyses for LBs in fetal lungs of SCH32615-treated animals (Fig. 4) . The relative numbers of LB-positive cells lining primitive alveoli were determined and the number of LBs per cell quantitated. A trend towards increased type II cell differentiation was observed on el 8 in SCH32615-treated animals (Fig. 4 A) cell (1.5-1.2, P < 0.005) in SCH32615-treated animals (Fig. 4  B) suggesting that CD1O/NEP inhibition may be associated with increased surfactant secretion.
Northern blot analyses. To further assess the effects of CD1O/NEP inhibition on fetal lung maturation, surfactant apoprotein transcript levels were determined as a highly specific indicator of ongoing surfactant synthesis. Northern blots were normalized using a pulmonary housekeeping G-protein (G-alpha,2) that is unchanged during normal lung development (31) . SP-A transcripts were detected at high levels in only one ofsix PBS control litters, as compared to three offive litters treated with SCH32615 (Fig. 4 A) . The SP-A transcripts were quantitated by densitometry (Fig. 5) and normalized for G-T T 7 Figure 5 . Relative levels ofsurfactant apoprotein mRNAs in fetal lung after CD10/NEP inhibition. Pregnant mice were treated with SCH32615 (1.0 mg/kg) from el5-17 and total RNA prepared from fetal lung tissues on e 18 using the GTC-CsCl method (19) . RNA from three to six mice per litter were pooled so that on Northern blots each lane represented a single litter. Relative SP-A, SP-B, and SP-C transcript levels were determined by densitometry, normalized for relative G-protein transcript levels, and expressed as mean percent change over baseline (PBS)±1 SE.
protein levels. As shown in Fig. 5 , the fivefold increase in SPA transcripts in SCH32615-treated animals was statistically significant (P < 0.05). SP-B and SP-C transcript levels were also increased by 50-60% in fetal lungs from SCH32615-treated animals (Fig. 5) .
Discussion
The present study demonstrates stimulation of fetal lung growth and maturation in mice treated in utero with SCH32615, a long acting CD1O/NEP inhibitor. Increased growth was evaluated using [3H]thymidine incorporation. Increased maturation was assessed using [3H]choline incorporation into SPC, ultrastructural morphometry for type II pneumocytes, and Northern blot analyses for SP-A, SP-B, and SP-C transcript levels. The effects of CD I0/NEP inhibition on thymidine and choline incorporation were blocked when animals were also treated with a specific bombesin receptor antagonist, implicating endogenous BLPs as mediators of the SCH32615 effect in vivo.
Both CD10/ NEP inhibition and the administration ofexogenous BLP stimulate fetal lung growth and maturation on e 18. In previous studies, peak levels of the mammalian bombesin homologue, GRP, were detectable on e 18 and exogenous BLP administration stimulated el 8 fetal lung growth and maturation (22) . That CD10/NEP inhibition similarly stimulates e 18 fetal lung growth and maturation is consistent with these observations. CD10/NEP inhibition has the greatest effects on fetal lung growth and maturation during the time frame in which endogenous fetal lung CD1O/NEP transcript levels are most abundant (-e [16] [17] [18] . Although SCH32615 administration in utero from e 12-14 had little effect on e 14 lung growth, significantly greater effects were seen at e 16-18. Similarly, SCH32615 administration from e 15-17 markedly enhanced e 18 fetal lung development. CD10/NEP is known to regulate the BLP-mediated autocrine growth ofSCLCs. The present study further indicates that the enzyme also regulates BLP-mediated paracrine growth and maturation of normal fetal lung. Since the in vivo administration of SCH32615 results in increased fetal lung maturation, CD10/NEP inhibition may be of therapeutic benefit for premature infants at high risk for developing hyaline membrane disease (33, 34) .
There are a number of parallels between the pulmonary and lymphoid expression of CD1O/NEP during normal fetal 
